134 related articles for article (PubMed ID: 9804700)
1. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
[TBL] [Abstract][Full Text] [Related]
2. 2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.
Hale JJ; Mills SG; MacCoss M; Shah SK; Qi H; Mathre DJ; Cascieri MA; Sadowski S; Strader CD; MacIntyre DE; Metzger JM
J Med Chem; 1996 Apr; 39(9):1760-2. PubMed ID: 8627597
[No Abstract] [Full Text] [Related]
3. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
[TBL] [Abstract][Full Text] [Related]
4. Investigating the effect of bilateral amygdala lesions on fear conditioning and social interaction in the male Mongolian gerbil.
Woolley ML; Haman M; Higgins GA; Ballard TM
Brain Res; 2006 Mar; 1078(1):151-8. PubMed ID: 16494851
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
7. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Duffy RA; Morgan C; Naylor R; Higgins GA; Varty GB; Lachowicz JE; Parker EM
Pharmacol Biochem Behav; 2012 Jul; 102(1):95-100. PubMed ID: 22497992
[TBL] [Abstract][Full Text] [Related]
8. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
9. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
Hale JJ; Mills SG; MacCoss M; Dorn CP; Finke PE; Budhu RJ; Reamer RA; Huskey SE; Luffer-Atlas D; Dean BJ; McGowan EM; Feeney WP; Chiu SH; Cascieri MA; Chicchi GG; Kurtz MM; Sadowski S; Ber E; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; Metzger JM; MacIntyre DE
J Med Chem; 2000 Mar; 43(6):1234-41. PubMed ID: 10737756
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.
Gerspacher M; Lewis C; Ball HA; Howes C; Subramanian N; Ryffel K; Fozard JR
J Med Chem; 2003 Jul; 46(16):3508-13. PubMed ID: 12877589
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
13. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.
Tattersall FD; Rycroft W; Cumberbatch M; Mason G; Tye S; Williamson DJ; Hale JJ; Mills SG; Finke PE; MacCoss M; Sadowski S; Ber E; Cascieri M; Hill RG; MacIntyre DE; Hargreaves RJ
Neuropharmacology; 2000 Feb; 39(4):652-63. PubMed ID: 10728886
[TBL] [Abstract][Full Text] [Related]
14. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy.
Maier DL; Sobotka-Briner C; Ding M; Powell ME; Jiang Q; Hill G; Heys JR; Elmore CS; Pierson ME; Mrzljak L
J Pharmacol Exp Ther; 2009 Jul; 330(1):342-51. PubMed ID: 19401496
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
16. Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs.
Tsuchida H; Takahashi S; Nosaka E; Kuraya T; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 Oct; 596(1-3):153-9. PubMed ID: 18706408
[TBL] [Abstract][Full Text] [Related]
17. Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements.
Ikeura Y; Ishichi Y; Tanaka T; Fujishima A; Murabayashi M; Kawada M; Ishimaru T; Kamo I; Doi T; Natsugari H
J Med Chem; 1998 Oct; 41(22):4232-9. PubMed ID: 9784098
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat.
Field MJ; McCleary S; Boden P; Suman-Chauhan N; Hughes J; Singh L
J Pharmacol Exp Ther; 1998 Jun; 285(3):1226-32. PubMed ID: 9618426
[TBL] [Abstract][Full Text] [Related]
19. Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist 'CJ-17,493'.
Shishido Y; Wakabayashi H; Koike H; Ueno N; Nukui S; Yamagishi T; Murata Y; Naganeo F; Mizutani M; Shimada K; Fujiwara Y; Sakakibara A; Suga O; Kusano R; Ueda S; Kanai Y; Tsuchiya M; Satake K
Bioorg Med Chem; 2008 Aug; 16(15):7193-205. PubMed ID: 18640044
[TBL] [Abstract][Full Text] [Related]
20. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
Di Fabio R; Griffante C; Alvaro G; Pentassuglia G; Pizzi DA; Donati D; Rossi T; Guercio G; Mattioli M; Cimarosti Z; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
J Med Chem; 2009 May; 52(10):3238-47. PubMed ID: 19388677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
